Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15R? complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15R? complexes are also provided.

Abstract: The present invention provides various PRAME binding molecules (including antibodies, antibody fragments, chimeric antigen receptors, and the like), compositions and cells (including T cells) comprising such PRAME binding molecules, and methods of using such PRAME binding molecules, compositions and cells, for example in the detection and/or monitoring of PRAME-positive tumors.

Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof comprise administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Abstract: Provided herein are methods of selecting a T cell line from among a collection of T cell lines for therapeutic administration to a human patient to treat a disease or disorder associated with a pathogen or to treat a cancer in the human patient. When the human patient has not been the recipient of any cellular transplant, the method involves excluding T cell lines restricted by only one HLA allele shared with the human patient and selecting a T cell line that is restricted to more than one HLA allele shared with the human patient and that exhibits a T cell response against an antigen of the pathogen or cancer.

Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (TSCM cells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.

Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15R? complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15R? complexes are also provided.

Abstract: The invention relates to methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.

Abstract: Provided herein are methods of treating a human patient, comprising administering to the human patient an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator and administering to the human patient a population of human cells comprising antigen-specific T cells that are derived from a T cell line restricted by a subdominant HLA allele or HLA allele combination. Also provided are methods of selecting such a T cell line and methods of selecting a T cell donor from whom to derive such a T cell line, for therapeutic administration to a human patient in combination with administration of an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator. Also provided are pharmaceutical compositions comprising an inhibitory immune checkpoint inhibitor or stimulatory immune checkpoint activator and a population of human cells comprising antigen-specific T cells that are derived from a T cell line restricted by a subdominant HLA allele or HLA allele combination.

Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.

Abstract: Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (TSCM cells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.

Abstract: Methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with human immunodeficiency virus (HIV) or has been the recipient of a solid organ transplant.

Abstract: Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.

Abstract: Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.

Abstract: Disclosed herein are methods of treating glioblastoma multiforme (GBM) in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV (cytomegalovirus)-specific T cells.

Abstract: Systems and methods for simulating and verifying a design are contemplated. Various embodiments determine a set of verification rules for a design, wherein the verification rules use a PSL or SVA syntax in a SPICE netlist to describ a property of the circuit design. The state of a circuit at a simulated first time, t1, can be determined. The state at the first time, t1, may be analyzed to determine if a triggering event has occurred. Based on the occurrence of the triggering event, the systems and methods can verify the state at the first time, t1, against the set of verification rules. Some embodiments of the systems and methods described herein can include a mixed-signal circuit including an analog portion and a digital portion, and the analog portion, the mixed-signal portion, or both, may be simulated and verified.

Abstract: A method and an apparatus for starting a gas turbine engine under various conditions are used to distribute a varying total amount of electric power to at least one of a starter, a fuel heater and an oil heater while providing fuel.

Abstract: A method of engine starting in a gas turbine engine comprises rotating the engine to provide an air flow into a combustor of the engine and injecting fuel into the combustor at a varying rate until the engine is lighted-off. The varying rate of the fuel flow is a function of time and is represented by a curve having at least one high frequency with respect to a light-off time, representing instant changes of the rate for intersecting a light-off zone while reducing a quantity of fuel injected into the combustor. After the light-off occurrence fuel is continuously injected into the combustor to accelerate the engine to a self-sustaining operation condition. This method of the present invention is adapted to find light-off points under various temperature and altitude conditions, thereby advantageously providing a rapid light-off, particularly under cold weather conditions.

Abstract: A method of engine starting in a gas turbine engine comprises rotating the engine to provide an air flow into a combustor of the engine and injecting fuel into the combustor at a varying rate until the engine is lighted-off. The varying rate of the fuel flow is a function of time and is represented by a curve having at least one high frequency with respect to a light-off time, representing instant changes of the rate for intersecting a light-off zone while reducing a quantity of fuel injected into the combustor. After the light-off occurrence fuel is continuously injected into the combustor to accelerate the engine to a self-sustaining operation condition. This method of the present invention is adapted to find light-off points under various temperature and altitude conditions, thereby advantageously providing a rapid light-off, particularly under cold weather conditions.

Abstract: A method of engine starting in a gas turbine engine comprises rotating the engine to provide an air flow into a combustor of the engine and injecting fuel into the combustor at a varying rate until the engine is lighted-off. The varying rate of the fuel flow is a function of time and is represented by a curve having at least one high frequency with respect to a light-off time, representing instant changes of the rate for intersecting a light-off zone while reducing a quantity of fuel injected into the combustor. After the light-off occurrence fuel is continuously injected into the combustor to accelerate the engine to a self-sustaining operation condition. This method of the present invention is adapted to find light-off points under various temperature and altitude conditions, thereby advantageously providing a rapid light-off, particularly under cold weather conditions.